Roger Li

List of Publications by Year in descending order

46 papers	684 citations	623188 14 h-index	610482 24 g-index
46 all docs	46 docs citations	46 times ranked	1042 citing authors

#	Article	IF	Citations
1	TGF-Î²-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	6.6	62
2	Reduced Dose Intravesical Bacillus Calmette-GuÃ©rin: Why It Might Not Matter. Bladder Cancer, 2022, 8, 113-117.	0.2	2
3	Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. European Urology Oncology, 2021, 4, 651-658.	2.6	25
4	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with nonâ€muscleâ€invasive bladder cancer treated with bacillus Calmetteâ€“GuÃ©rin. BJU International, 2021, 128, 65-71.	1.3	13
5	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 140-149.	2.0	15
6	Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-GuÃ©rin. European Urology, 2021, 80, 1-3.	0.9	11
7	Impact of upper tract urothelial carcinoma on response to BCG in patients with nonâ€muscleâ€invasive bladder cancer. BJU International, 2021, 128, 568-574.	1.3	2
8	Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-GuÃ©rin Therapy Outcomes. European Urology Oncology, 2021, , .	2.6	1
9	The Who, What, When, Where, and Why of Bacillus Calmette-GuÃ©rin-unresponsive Bladder Cancer. European Urology, 2021, 79, 437-439.	0.9	3
10	Time interval from transurethral resection of bladder tumour to bacille Calmetteâ€“GuÃ©rin induction does not impact therapeutic response. BJU International, 2021, 128, 634-641.	1.3	5
11	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. European Urology Oncology, 2021, 4, 893-903.	2.6	31
12	Reply by Authors. Journal of Urology, 2021, 205, 1620-1621.	0.2	0
13	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-GuÃ©rin: Implications for Clinical Trial Design. Journal of Urology, 2021, 205, 1612-1621.	0.2	31
14	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nature Reviews Urology, 2021, 18, 543-555.	1.9	20
15	Oncologic Equipoise Between Robotic and Open Radical Cystectomy. Journal of Endourology, 2021, 35, 1168-1176.	1.1	1
16	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Journal of Urology, 2021, 206, 548-557.	0.2	9
17	Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. Journal of Urology, 2021, 206, 646-654.	0.2	2
18	Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713â€“6. European Urology, 2021, 80, e99.	0.9	0

#	Article	IF	Citations
19	Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, , .	0.8	0
20	Malignant solitary fibrous tumour of the prostate: four cases emphasising significant histological and immunophenotypical overlap with sarcomatoid carcinoma. Pathology, 2020, 52, 643-648.	0.3	8
21	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Nonâ€“muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-GuÃ©rin. European Urology, 2020, 78, 387-399.	0.9	28
22	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 796.e1-796.e6.	0.8	13
23	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Communications Biology, 2020, 3, 784.	2.0	21
24	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-GuÃ©rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Journal of Urology, 2020, 203, 283-291.	0.2	10
25	Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4â€“6. European Urology, 2019, 76, e34.	0.9	0
26	Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. European Urology, 2019, 76, 4-6.	0.9	8
27	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World Journal of Urology, 2019, 37, 2691-2698.	1.2	10
28	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 354.e19-354.e26.	0.8	4
29	Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. European Urology Oncology, 2019, 2, 286-293.	2.6	8
30	Detection and Treatment of Primary Prostatic Melanoma. Urology, 2019, 123, 16-19.	0.5	6
31	Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. European Urology, 2019, 75, 8-10.	0.9	31
32	Endoscopic Approaches to Upper Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 267-286.	0.8	23
33	Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. Bladder Cancer, 2018, 4, 31-40.	0.2	15
34	Secondary Tumors After Urinary Diversion. Urologic Clinics of North America, 2018, 45, 91-99.	0.8	4
35	Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. European Urology, 2018, 74, 405-408.	0.9	12
36	Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology, 2018, 116, 114-119.	0.5	19

#	Article	IF	Citations
37	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We There Yet? A Systematic Review. European Urology, 2018, 73, 738-748.	0.9	112
38	Characterization of Glomus Tumors of the Kidney. Clinical Genitourinary Cancer, 2018, 16, e253-e256.	0.9	2
39	Effects of thiazolidinedione in patients with active bladder cancer. BJU International, 2018, 121, 244-251.	1.3	3
40	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70
41	Extended Pelvic Lymph Node Dissection in Bladder Cancer. Journal of Endourology, 2018, 32, S-49-S-54.	1.1	3
42	Applying translabial ultrasound to detect synthetic slings-You can do it too! A comparison of urology trainees to an attending radiologist. Neurourology and Urodynamics, 2017, 36, 1763-1769.	0.8	6
43	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer, 2017, 3, 147-148.	0.2	2
44	Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) inÂBCG-Unresponsive Patients. Bladder Cancer, 2017, 3, 65-71.	0.2	24
45	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investigative and Clinical Urology, 2016, 57, S155.	1.0	4
46	New discoveries in the molecular landscape of bladder cancer. F1000Research, 2016, 5, 2875.	0.8	5